MY153065A - Cytokine inhibitors - Google Patents

Cytokine inhibitors

Info

Publication number
MY153065A
MY153065A MYPI20101943A MY153065A MY 153065 A MY153065 A MY 153065A MY PI20101943 A MYPI20101943 A MY PI20101943A MY 153065 A MY153065 A MY 153065A
Authority
MY
Malaysia
Prior art keywords
cytokine inhibitors
compound
cytokine
formula
relates
Prior art date
Application number
Other languages
English (en)
Inventor
Deng Wei
Su Wei-Guo
Cai Yu
Duan Jeff
Original Assignee
Hutchison Medipharma Entpr Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchison Medipharma Entpr Ltd filed Critical Hutchison Medipharma Entpr Ltd
Publication of MY153065A publication Critical patent/MY153065A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MYPI20101943 2007-11-02 2008-10-31 Cytokine inhibitors MY153065A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/934,154 US7868001B2 (en) 2007-11-02 2007-11-02 Cytokine inhibitors

Publications (1)

Publication Number Publication Date
MY153065A true MY153065A (en) 2014-12-31

Family

ID=40588767

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20101943 MY153065A (en) 2007-11-02 2008-10-31 Cytokine inhibitors

Country Status (11)

Country Link
US (1) US7868001B2 (enExample)
EP (1) EP2214669B1 (enExample)
JP (1) JP5733982B2 (enExample)
KR (1) KR20100101581A (enExample)
AU (1) AU2008318491B2 (enExample)
CA (1) CA2704431A1 (enExample)
MX (1) MX2010004774A (enExample)
MY (1) MY153065A (enExample)
RU (1) RU2485113C2 (enExample)
TW (1) TWI419692B (enExample)
WO (1) WO2009059162A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH066861Y2 (ja) 1991-02-19 1994-02-23 太陽電子株式会社 パチンコ式組合せゲーム機
PL2485731T4 (pl) * 2009-10-06 2017-07-31 Millennium Pharmaceuticals, Inc. Związki heterocykliczne użyteczne jako inhibitory PDK1
WO2011137587A1 (en) * 2010-05-06 2011-11-10 Hutchison Medipharma Limited Cytokine inhibitors
FR2962649B1 (fr) 2010-07-19 2025-10-24 Conservatoire Nat Arts Et Metiers Traitement d'une pathologie liee a un effet excessif du tnf par un compose de benzene sulfonamide
RS57508B1 (sr) 2013-09-06 2018-10-31 Aurigene Discovery Tech Ltd 1,2,4-derivati oksadiazola kao imunomodulatori
EA201650031A1 (ru) 2014-05-15 2017-06-30 Итеос Терапьютик Производные пирролидин-2,5-диона, фармацевтические композиции и способы применения в качестве ингибиторов ido1
KR102302109B1 (ko) * 2014-07-24 2021-09-14 삼성디스플레이 주식회사 유기 화합물 및 이를 포함하는 유기 발광 장치
KR102894264B1 (ko) 2015-03-10 2025-12-02 오리진 온콜로지 리미티드 면역조절제로서의 1,2,4-옥사다이아졸 및 티아다이아졸 화합물
BR112017019699A2 (pt) 2015-03-17 2018-09-04 Pfizer Inc. derivados substituídos por 3-indol, composições farmacêuticas e métodos para uso
US10544095B2 (en) 2015-08-10 2020-01-28 Pfizer Inc. 3-indol substituted derivatives, pharmaceutical compositions and methods for use
US20170107216A1 (en) 2015-10-19 2017-04-20 Incyte Corporation Heterocyclic compounds as immunomodulators
MD3377488T2 (ro) 2015-11-19 2023-02-28 Incyte Corp Compuși heterociclici ca imunomodulatori
ES2916874T3 (es) 2015-12-17 2022-07-06 Incyte Corp Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1
CA3009474A1 (en) 2015-12-22 2017-06-29 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2906460T3 (es) 2016-05-06 2022-04-18 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
EP3464279B1 (en) 2016-05-26 2021-11-24 Incyte Corporation Heterocyclic compounds as immunomodulators
SG11201811414TA (en) 2016-06-20 2019-01-30 Incyte Corp Heterocyclic compounds as immunomodulators
MA45669A (fr) 2016-07-14 2019-05-22 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
US20180057486A1 (en) 2016-08-29 2018-03-01 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018118781A1 (en) * 2016-12-20 2018-06-28 Fmc Corporation Fungicidal oxadiazoles
WO2018119286A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
WO2018119221A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
EP4223369A1 (en) 2016-12-22 2023-08-09 Incyte Corporation Immunomodulator compounds and methods of use
US10308644B2 (en) 2016-12-22 2019-06-04 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018119236A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
WO2019061324A1 (en) 2017-09-29 2019-04-04 Curis Inc. CRYSTALLINE FORMS OF IMMUNOMODULATORS
AU2018348350B2 (en) 2017-10-11 2024-05-02 Aurigene Oncology Limited Crystalline forms of 3-substituted 1,2,4-oxadiazole
MX2020004531A (es) 2017-11-03 2020-08-03 Aurigene Discovery Tech Ltd Inhibidores dobles de tim-3 y las vias de pd-1.
EP3706798A1 (en) 2017-11-06 2020-09-16 Aurigene Discovery Technologies Limited Conjoint therapies for immunomodulation
SMT202300065T1 (it) 2018-03-30 2023-05-12 Incyte Corp Composti eterociclici come immunomodulatori
CN112752756B (zh) 2018-05-11 2024-06-25 因赛特公司 作为PD-L1免疫调节剂的四氢-咪唑并[4,5-c]吡啶衍生物
TW202115059A (zh) 2019-08-09 2021-04-16 美商英塞特公司 Ｐｄ—１／ｐｄ—ｌ１抑制劑之鹽
US20220267270A1 (en) * 2019-08-30 2022-08-25 University Of South Florida Sting modulators, compositions, and methods of use
JP7559059B2 (ja) 2019-09-30 2024-10-01 インサイト・コーポレイション 免疫調節剤としてのピリド［３，２－ｄ］ピリミジン化合物
EP4058461A1 (en) 2019-11-11 2022-09-21 Incyte Corporation Salts and crystalline forms of a pd-1/pd-l1 inhibitor
IL297963A (en) 2020-05-07 2023-01-01 Adorx Therapeutics Ltd Antagonists of the adenosine a2a receptor
IL302590A (en) 2020-11-06 2023-07-01 Incyte Corp Process for preparing PD-1/PD-L1 inhibitor and salts and crystalline forms thereof
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
US11760756B2 (en) 2020-11-06 2023-09-19 Incyte Corporation Crystalline form of a PD-1/PD-L1 inhibitor
GB202019622D0 (en) * 2020-12-11 2021-01-27 Adorx Therapeutics Ltd Antagonist compounds

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5745237B2 (enExample) * 1974-03-27 1982-09-27
GB1442707A (en) * 1973-07-07 1976-07-14 Yoshitomi Pharmaceutical Substituted phenylalkanoic acids and their derivatives and pharma ceutical compositions thereof
DE3446812A1 (de) 1984-12-21 1986-06-26 Dr. Karl Thomae Gmbh, 7950 Biberach Neue imidazoderivate, ihre herstellung und diese verbindungen enthaltende arzneimittel
DE3446778A1 (de) 1984-12-21 1986-07-03 Dr. Karl Thomae Gmbh, 7950 Biberach Neue imidazoderivate, ihre herstellung und diese verbindungen enthaltende arzneimittel
IL86462A (en) * 1987-05-29 1992-12-01 Fujisawa Pharmaceutical Co Alkanesulfonanilide derivatives, processes for preparation thereof and pharmaceutical compositions comprising the same
WO1989001478A1 (en) * 1987-08-07 1989-02-23 The Australian National University ARYLOXY- AND ARALKYLTHIO-IMIDAZO[1,2-b]PYRIDAZINES
DE4405378A1 (de) * 1994-02-19 1995-08-24 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
JPH07291976A (ja) * 1994-04-27 1995-11-07 Otsuka Pharmaceut Factory Inc イミダゾ〔２，１−ｂ〕チアゾール誘導体
JP3477238B2 (ja) * 1994-04-27 2003-12-10 株式会社大塚製薬工場 イミダゾ〔１，２−ａ〕ピリジン誘導体
UA73492C2 (en) * 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
DE60010448T2 (de) * 1999-03-17 2005-04-07 Astrazeneca Ab Amid-derivate
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
CA2397661C (en) * 2000-03-01 2012-01-03 Janssen Pharmaceutica N.V. 2,4-disubstituted thiazolyl derivatives
WO2002049632A1 (en) * 2000-12-18 2002-06-27 Institute Of Medicinal Molecular Design. Inc. Inhibitors against the production and release of inflammatory cytokines
US6596731B2 (en) * 2001-03-27 2003-07-22 Hoffmann-La Roche Inc. Substituted imidazo[1,2-A] pyridine derivatives
CA2450555A1 (en) * 2001-06-25 2003-01-03 Merck & Co., Inc. (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds
EP1426050A4 (en) * 2001-08-23 2005-05-25 Takeda Pharmaceutical JNK INHIBITORS
ATE511858T1 (de) * 2002-02-05 2011-06-15 Astellas Pharma Inc 2,4,6-triamino-1,3,5-triazin-derivat
US7105533B2 (en) * 2002-09-13 2006-09-12 Merck & Co., Inc. Fused heterobicyclo substituted phenyl metabotropic glutamate-5 modulators
JP2006516250A (ja) 2002-12-18 2006-06-29 サイトビア インコーポレイティッド カスパーゼ活性化剤およびアポトーシス誘導物質としての３，５−二置換−［１，２，４］−オキサジアゾールおよびそれらの誘導体ならびにそれらの使用
RU2006100301A (ru) 2003-06-11 2006-07-10 Санкио Компани Лимитед (JP) Соединение циклического третичного амина
CA2551867C (en) 2003-12-31 2010-08-17 Schering-Plough Ltd. Control of parasites in animals by the use of imidazo[1,2-b]pyridazine derivatives
JP2008504294A (ja) * 2004-06-25 2008-02-14 アムジエン・インコーポレーテツド サイトカイン介在疾患および他の疾患の治療において有用な縮合トリアゾールおよびインダゾール
US20060064650A1 (en) * 2004-09-20 2006-03-23 International Business Machines Corporation Method, system, and computer program product for type-based table navigation
KR20070057965A (ko) * 2004-09-21 2007-06-07 신타 파마슈티칼스 코프. 염증 및 면역 관련 용도를 위한 화합물
EP1812439B2 (en) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
JPWO2006070943A1 (ja) * 2004-12-28 2008-06-12 武田薬品工業株式会社 縮合イミダゾール化合物およびその用途
US20090163476A1 (en) * 2005-03-03 2009-06-25 Sirtris Pharmaceuticals, Inc. N-Phenyl Benzamide Derivatives as Sirtuin Modulators
US7345178B2 (en) * 2005-08-04 2008-03-18 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
DE102005042742A1 (de) * 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
WO2007034278A2 (en) 2005-09-19 2007-03-29 Pfizer Products Inc. Fused imidazole derivatives as c3a receptor antagonists
AU2006311786A1 (en) * 2005-11-04 2007-05-18 Merck Sharp & Dohme Corp. Diphenylmethane derivatives as inhibitors of leukotriene biosynthesis
DE102006011574A1 (de) * 2006-03-10 2007-10-31 Grünenthal GmbH Substituierte Imidazo[2,1-b]thiazol-Verbindungen und ihre Verwendung zur Herstellung von Arzneimitteln
EP1845098A1 (en) * 2006-03-29 2007-10-17 Ferrer Internacional, S.A. Imidazo[1,2-b]pyridazines, their processes of preparation and their use as GABA receptor ligands
WO2007123892A2 (en) * 2006-04-17 2007-11-01 Arqule Inc. Raf inhibitors and their uses
US20080015193A1 (en) 2006-06-20 2008-01-17 Mendoza Jose S Certain azoles exhibiting ATP-utilizing enzyme inhibitory activity, compositions, and uses thereof
EP1964841A1 (en) 2007-02-28 2008-09-03 sanofi-aventis Imidazo[1,2-a]azine and their use as pharmaceuticals
CA2707360A1 (en) * 2007-06-20 2008-12-24 Merck Sharp & Dohme Corp. Diphenyl substituted alkanes
FR2918061B1 (fr) * 2007-06-28 2010-10-22 Sanofi Aventis Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique.
FR2918986B1 (fr) * 2007-07-19 2009-09-04 Sanofi Aventis Sa Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique
CA2695251C (en) * 2007-08-14 2016-06-21 Bayer Schering Pharma Aktiengesellschaft Fused imidazoles for cancer treatment
EP2083009A1 (de) * 2008-01-22 2009-07-29 Grünenthal GmbH Substituierte Tethrahydroimidazopyridin-Verbindungen und deren Verwendung in Arzneimitteln
CA2722418C (en) 2008-05-13 2013-09-17 Irm Llc Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors
PA8854101A1 (es) * 2008-12-18 2010-07-27 Ortho Mcneil Janssen Pharm Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa

Also Published As

Publication number Publication date
KR20100101581A (ko) 2010-09-17
EP2214669B1 (en) 2015-04-01
RU2485113C2 (ru) 2013-06-20
WO2009059162A1 (en) 2009-05-07
CA2704431A1 (en) 2009-05-07
MX2010004774A (es) 2010-07-02
EP2214669A1 (en) 2010-08-11
RU2010122333A (ru) 2011-12-10
JP2011502996A (ja) 2011-01-27
TWI419692B (zh) 2013-12-21
US20090118292A1 (en) 2009-05-07
AU2008318491A1 (en) 2009-05-07
JP5733982B2 (ja) 2015-06-10
US7868001B2 (en) 2011-01-11
EP2214669A4 (en) 2011-11-09
AU2008318491B2 (en) 2013-09-19
TW201002327A (en) 2010-01-16

Similar Documents

Publication Publication Date Title
MX2010004774A (es) Inhibidores de citoquina.
MX353308B (es) Derivados fosforosos como inhibidores de cinasa.
NZ598516A (en) Quinazolines as potassium ion channel inhibitors
WO2008128072A3 (en) Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders
AU2010230585A8 (en) Autotaxin inhibitors
AU2009319796A8 (en) Substituted octahydrocyclopnta (c) pyrrol-4 -amines as calcium channel blockers
WO2011097301A3 (en) METHODS AND COMPOSITIONS FOR PREDICTING RESPONSIVENESS TO TREATMENT WITH TNF-α INHIBITOR
EA201170521A1 (ru) Новые соединения
IN2012DN03883A (enExample)
PH12013502049A1 (en) Modulation of signal transducer and activator of transcription 3 (stat3) expression
MX359146B (es) Compuesto como inhibidor de señalización wnt, composición y uso de los mismos.
EA201170052A1 (ru) Производные тиофена или тиазола и их применение как ингибиторов pi3k
SG169988A1 (en) Rnai inhibition of alpha-enac expression
MX2009002377A (es) Derivados de indazol como moduladores de cinasa asociados con el receptor de interleucina-1.
EA201400170A1 (ru) Композиции и способы для ингибирования экспрессии транстиретина
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
MX2010009416A (es) Compuestos heterociclicos como inhibidores de cxcr2.
MY163852A (en) Amidophenoxyindazoles useful as inhibitors of c-met.
EP3715457A3 (en) Modulation of prekallikrein (pkk) expression
EA201070238A1 (ru) Соединения пиримидина
WO2012118903A3 (en) Sclerostin and dkk-1 bispecific binding agents
WO2010033701A3 (en) Inhibitors of sphingosine kinase 1
MX340756B (es) Compuestos de quinazolina como inhibidores de serina/treonina quinasa.
MX337190B (es) Nuevas bencensulfonamidas como bloqueadores del canal de calcio.
WO2013003298A3 (en) Inhibitors of pde10